TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04194684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.
Study: NCT01582984

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video or education session in addition to standard consent
Description: Video added to standard consent + handout Video + education session added to standard consent + handout

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video or education session in addition to standard consent
Description: Video added to standard consent + handout Video + education session added to standard consent + handout

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video or education session in addition to standard consent
Description: Video added to standard consent + handout Video + education session added to standard consent + handout
Study: NCT01202071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium, 5 mg Tablets
Description: Rabeprazole sodium Tablets, 5 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium, 10 mg Tablets
Description: Rabeprazole sodium Tablets, 10 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium, 20 mg Tablets
Description: Rabeprazole sodium Tablets, 20 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)
Description: Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water, \>=2 hours after the completion of breakfast.
Study: NCT02172482

Intervention type: DRUG
Intervention: Tiotropium bromide
Description: Tiotropium bromide18 micrograms (capsule with powder for inhalation)
Study: NCT03265067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoRIC
Description: Application of the autoRIC device
Study: NCT01000493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orvepitant
Description: Neurokinin-1 (NK-1) antagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo to match orvepitant 60 mg dosage form
Study: NCT01988168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture closure
Description: A running subcuticular suture is placed by taking horizontal bites through the papillary dermis on alternating sides of the wound. An absorbable suture is used and left in place until degraded and absorbed by the patient's tissues.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staples closure
Description: Surgical stapling devices re-appose skin edges with stainless steel or titanium staples. A second operator everts the wound skin edges while the operator applies staples along the incision. Staples can be removed on post-operative day 2 or 3, or delayed further according the surgeon preference based on patient characteristics.
Study: NCT04707586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Created by the researcher; A bandage with 3 pieces of 13x10 cm cold gel and a cold gel container in which they are placed will be used, which can be adjusted according to the head circumference of the patient between 60-80 cm in length. The ability of the cold gel cups of the bandage to be moved on the bandage will allow comfortable cold application to the patient's bilateral frontotemporal and occipital areas at the same time. After waiting for 20 minutes in the freezer part of the refrigerator, the temperature and temperature of the gels applied and the cold application area before and after each application will be measured and recorded. An Infrared Non-Contact Food Thermometer will be used for temperature measurement of cold gel packs, and an Infrared Non-Contact Thermometer device will be used for temperature measurement of the cold application area.
Study: NCT02856009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completion of a quality of life questionnaire
Study: NCT01905709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human fecal matter
Study: NCT04487444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: Synthetic 28 amino acid peptide identical to naturally circulating compound
Study: NCT03180229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron 1 Mg/mL Intravenous Solution
Description: 1 milligram (mg) will use on group Granisetron before 5 min induction
Study: NCT03733327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.
Study: NCT02540746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement
Description: Three week Motivational Enhancement group
Study: NCT00387920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02221908

Intervention type: DEVICE
Intervention: Mespere Venus 1000 CVP System
Study: NCT03201679

Intervention type: PROCEDURE
Intervention: Repair of hip fracture
Description: Patients undergoing hip fracture surgery

Intervention type: PROCEDURE
Intervention: Repair of hip fracture
Description: Patients undergoing hip fracture surgery
Study: NCT03733327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT03261479

Intervention type: DIAGNOSTIC_TEST
Intervention: Thermal image
Description: We will take a non-invasive thermal image with the FLIR ONE thermal imaging camera that attaches to a study-designated iPhone.
Study: NCT00625898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B
Study: NCT03733327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16)
Description: Etoposide was administered at 15 mg/kg/day on days -3 to -2.
Study: NCT03426527

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine-Dexmedetomidine
Description: Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine in conjunction with dexmedetomidine
Study: NCT01674647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
Study: NCT03426527

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General Anaesthesia
Description: Using propofol, fentanyl and atracurium

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Anaesthesia
Description: Using propofol, fentanyl and atracurium
Study: NCT02408627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Study: NCT04246450

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator (ICD) insertion
Description: Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF\<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF \<35%. In patients in the LVEF \<35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.
Study: NCT01988077

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Adoptive cell transfer
Description: Adoptive cell transfer

Intervention type: DRUG
Group type: OTHER
Intervention: Ipilimumab 5 MG/ML Injection [Yervoy]
Description: 2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
Study: NCT03057184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
Study: NCT01822925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9801 300mg
Description: 300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9801 600mg
Description: 600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9801 900mg
Description: 900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
Study: NCT01161771

Intervention type: PROCEDURE
Intervention: Cataract Surgery and Limbal relaxing incision
Description: Cataract extraction and limbal-relaxing incisions
Study: NCT02540746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Skills Training
Description: 12-week group-based family skills training using Family Connections model
Study: NCT00625898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: 6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Study: NCT04534036

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PDS-08
Description: PDS-08 is a novel synbiotic comprised of nine probiotic bacterial strains and FOS-inulin as a prebiotic.
Study: NCT01385891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine VP 16 ciclophospahamide
Description: Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
Study: NCT03707691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening tests. Pitch training protocol
Description: The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening tests. Pitch training protocol
Description: The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening tests. Pitch training protocol
Description: The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visuo-spatial training protocol
Description: The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visuo-spatial training protocol
Description: The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visuo-spatial training protocol
Description: The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EEG/MEG/MRI recordings.
Description: Listening tests. EEG/MEG/MRI recordings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EEG/MEG/MRI recordings.
Description: Listening tests. EEG/MEG/MRI recordings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EEG/MEG/MRI recordings.
Description: Listening tests. EEG/MEG/MRI recordings
Study: NCT03234088

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Daily weight measured by digital scale and symptom reporting
Description: All subjects will be provided the intervention.
Study: NCT01591304

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.
Study: NCT01185782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonalef® (Follitropin alfa)
Description: Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purified pituitary gonadotropin (Fertinorm-P®)
Description: Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
Study: NCT01998711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory group
Description: Five 1-1.5 hour weekly session of memory training
Study: NCT03133039

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery, bioabsorbable screw
Description: In this study we compare bioabsorbable and titanium screw in the hallux valgus and hallux rigidus surgery
Study: NCT04246450

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator (ICD) insertion
Description: Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF\<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF \<35%. In patients in the LVEF \<35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator (ICD) insertion
Description: Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF\<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF \<35%. In patients in the LVEF \<35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator (ICD) insertion
Description: Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF\<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF \<35%. In patients in the LVEF \<35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.
Study: NCT02154776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: 3 weeks on and 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg daily;
Study: NCT05108662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery method
Description: Patients were subdivided into two groups according to their prostate volume

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery method
Description: Patients were subdivided into two groups according to their prostate volume